Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – X-ray contrast imaging agent
Reexamination Certificate
2011-07-19
2011-07-19
Desai, Anand U (Department: 1656)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
X-ray contrast imaging agent
C530S300000, C530S350000, C514S002600
Reexamination Certificate
active
07981400
ABSTRACT:
The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3receptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T whereinSTxB is the Shiga Toxin B subunit or a functional equivalent thereof,Z(n) wherein n is 0 or 1 and when n is 1, Z is an amino-acid residue devoid of sulfhydryl group, or is a polypeptide,Cys is the amino-acid residue for Cysteine,T is a molecule linked by a covalent bound to the S part of Cys, selected in a group comprising:agents for in vivo diagnosis,cytotoxic agents,prodrugs, orenzymes for the conversion of a prodrug to a drug,Y(m) wherein m is 0 or 1 and when m is 1, Y is a linker between T and Cys, said linker being either cleavable or not cleavable for the release of T after the internalization of the hybrid compound into said cells.
REFERENCES:
patent: 4782113 (1988-11-01), Maeda et al.
patent: 4827945 (1989-05-01), Groman et al.
patent: 5053423 (1991-10-01), Liu
patent: 5250565 (1993-10-01), Brooks et al.
patent: 5753627 (1998-05-01), Albert et al.
patent: 5807879 (1998-09-01), Rosebrough
patent: 5840485 (1998-11-01), Lebl et al.
patent: 5994311 (1999-11-01), Eichner et al.
patent: 6348446 (2002-02-01), Gariepy
patent: 6368598 (2002-04-01), D'Amico
patent: 7112317 (2006-09-01), Thorpe et al.
patent: 2004/0110935 (2004-06-01), Johannes et al.
patent: 1 229 045 (2002-08-01), None
patent: WO 95/11998 (1995-05-01), None
patent: WO 97/25067 (1997-07-01), None
patent: WO 00/61183 (2000-10-01), None
patent: WO 02/02147 (2002-01-01), None
patent: WO 02/060937 (2002-08-01), None
Haicheur et al., “The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens”, J. of Immunology, vol. 165, No. 6 (2000) pp. 3301-3308.
Johannes L et al., “Retrograde transport of KDEL-bearing B-fragment of Shiga toxin”, The Journal of Biological Chemistry. United States, Aug. 1, 1997, vol. 272, No. 31, pp. 19554-19561.
Sandvig et al., “Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives”, The EMBO Journal, vol. 19, No. 22 (2000) pp. 5943-5950.
Schelte P. et al., “Technical Notes Differential Reactivity of Maleimide and Bromoacetyl Functions with Thiols: Application to the Preparation of Liposomal Diepitope Constructs”, Bioconjugate Chemistry, American Chemical Society, Washington, US, vol. 11, No. 1, Jan. 2000, pp. 118-123.
Florent Jean-Claude
Grierson David
Johannes Ludger
Maillard Philipe
Robine Sylvie
Birch Stewart Kolasch & Birch, LLP.
Centre National de la Recherche Scientifique
Desai Anand U
Institut Curie
Institut National de la Sante et de la Recherche Medicale
LandOfFree
Shiga toxin B-subunit as a vector for tumor diagnosis and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Shiga toxin B-subunit as a vector for tumor diagnosis and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Shiga toxin B-subunit as a vector for tumor diagnosis and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2670513